Journal Of Thoracic Oncology SCIE

国际简称：J THORAC ONCOL 参考译名：胸部肿瘤学杂志

主要研究方向：医学-呼吸系统非预警期刊审稿周期：一般,3-6周

《胸部肿瘤学杂志》(Journal Of Thoracic Oncology)是一本由International Association for the Study of Lung Cancer出版的以医学-呼吸系统为研究特色的国际期刊，发表该领域相关的原创研究文章、评论文章和综述文章，及时报道该领域相关理论、实践和应用学科的最新发现，旨在促进该学科领域科学信息的快速交流。该期刊是一本未开放期刊，近三年没有被列入预警名单。该期刊享有很高的科学声誉，影响因子不断增加，发行量也同样高。

1区中科院分区
Q1 JCR分区
100 年发文量
21 IF影响因子
未开放 是否OA
113 H-index
2006 创刊年份
Monthly 出版周期
English 出版语言

Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO emphasizes a multidisciplinary approach and includes original research reviews and opinion pieces. The audience includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.

[ 查看全部 ]

投稿咨询加急咨询

Journal Of Thoracic Oncology期刊信息

ISSN：1556-0864
出版语言：English
是否OA：未开放
E-ISSN：1556-1380
出版地区：UNITED STATES
是否预警：否
出版商：International Association for the Study of Lung Cancer
出版周期：Monthly
创刊时间：2006
开源占比：0.3402
Gold OA文章占比：83.71%
OA被引用占比：0.1724...
出版国人文章占比：0.14
出版撤稿占比：0
研究类文章占比：88.00%

Journal Of Thoracic Oncology CiteScore评价数据（2024年最新版）

CiteScore

SJR

SNIP

CiteScore 指数

7.879

3.906

学科类别	分区	排名	百分位
大类：Medicine 小类：Pulmonary and Respiratory Medicine	Q1	2 / 155	99%
大类：Medicine 小类：Oncology	Q1	11 / 404	97%

名词解释：CiteScore 是衡量期刊所发表文献的平均受引用次数，是在 Scopus 中衡量期刊影响力的另一个指标。当年CiteScore 的计算依据是期刊最近4年（含计算年度）的被引次数除以该期刊近四年发表的文献数。例如，2022年的 CiteScore 计算方法为：2022年的 CiteScore =2019-2022年收到的对2019-2022年发表的文件的引用数量÷2019-2022年发布的文献数量注：文献类型包括：文章、评论、会议论文、书籍章节和数据论文。

Journal Of Thoracic Oncology中科院评价数据

中科院 2023年12月升级版

Top期刊	综述期刊	大类学科		小类学科
是	否	医学	1区	ONCOLOGY 肿瘤学 RESPIRATORY SYSTEM 呼吸系统	1区 1区

中科院 2022年12月升级版

Top期刊	综述期刊	大类学科		小类学科
是	否	医学	1区	ONCOLOGY 肿瘤学 RESPIRATORY SYSTEM 呼吸系统	1区 1区

中科院 2021年12月旧的升级版

Top期刊	综述期刊	大类学科		小类学科
是	否	医学	1区	ONCOLOGY 肿瘤学 RESPIRATORY SYSTEM 呼吸系统	1区 1区

中科院 2021年12月基础版

Top期刊	综述期刊	大类学科		小类学科
是	否	医学	1区	ONCOLOGY 肿瘤学 RESPIRATORY SYSTEM 呼吸系统	1区 1区

中科院 2021年12月升级版

Top期刊	综述期刊	大类学科		小类学科
是	否	医学	1区	ONCOLOGY 肿瘤学 RESPIRATORY SYSTEM 呼吸系统	1区 1区

中科院 2020年12月旧的升级版

Top期刊	综述期刊	大类学科		小类学科
是	否	医学	1区	ONCOLOGY 肿瘤学 RESPIRATORY SYSTEM 呼吸系统	1区 1区

Journal Of Thoracic Oncology JCR评价数据（2023-2024年最新版）

按JIF指标学科分区	收录子集	分区	排名	百分位
学科：ONCOLOGY	SCIE	Q1	13 / 322	96.1%
学科：RESPIRATORY SYSTEM	SCIE	Q1	2 / 100	98.5%

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：ONCOLOGY	SCIE	Q1	12 / 322	96.43%
学科：RESPIRATORY SYSTEM	SCIE	Q1	2 / 101	98.51%

Journal Of Thoracic Oncology历年数据统计

影响因子

中科院分区

Journal Of Thoracic Oncology中国学者发文选摘

1、Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC
Author: Naidoo, Jarushka; Antonia, Scott; Wu, Yi-Long; Cho, Byoung Chul; Thiyagarajah, Piruntha; Mann, Helen; Newton, Michael; Faivre-Finn, Corinne

Journal: JOURNAL OF THORACIC ONCOLOGY. 2023; Vol. 18, Issue 5, pp. 657-663. DOI: 10.1016/j.jtho.2023.02.009
2、Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial
Author: Zhou, Caicun; Huang, Dingzhi; Fan, Yun; Yu, Xinmin; Liu, Yunpeng; Shu, Yongqian; Ma, Zhiyong; Wang, Ziping; Cheng, Ying; Wang, Jie; Hu, Sheng; Liu, Zhihua; Poddubskaya, Elena; Disel, Umut; Akopov, Andrey; Dvorkin, Mikhail; Zheng, Wenjuan; Ma, Yiyuan; Wang, Yan; Li, Songzi; Yu, Cunjing; Rivalland, Gareth

Journal: JOURNAL OF THORACIC ONCOLOGY. 2023; Vol. 18, Issue 1, pp. 93-105. DOI: 10.1016/j.jtho.2022.09.217
3、NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC
Author: de Castro Jr, Gilberto; Rizvi, Naiyer A.; Schmid, Peter; Syrigos, Konstantinos; Martin, Claudio; Yamamoto, Nobuyuki; Cheng, Ying; Moiseyenko, Vladimir; Summers, Yvonne; Vynnychenko, Ihor; Lee, Sung Yong; Bryl, Maciej; Zer, Alona; Erman, Mustafa; Timcheva, Constanta; Raja, Rajiv; Naicker, Kirsha; Scheuring, Urban; Walker, Jill; Mann, Helen; Chand, Vikram; Mok, Tony

Journal: JOURNAL OF THORACIC ONCOLOGY. 2023; Vol. 18, Issue 1, pp. 106-119. DOI: 10.1016/j.jtho.2022.09.223
4、Adebrelimab (SHR-1316) in Combination With Chemotherapy as Perioperative Treatment in Patients With Resectable Stage II to III NSCLCs: An Open-Label, Multicenter, Phase 1b Trial
Author: Yan, Wanpu; Zhong, Wen-Zhao; Liu, Yan-Hui; Chen, Qixun; Xing, Wenqun; Zhang, Qin; Liu, Lunxu; Ge, Di; Chen, Keneng; Yang, Fan; Lin, Xiang; Song, Li; Shi, Wei; Wu, Yi-Long

Journal: JOURNAL OF THORACIC ONCOLOGY. 2023; Vol. 18, Issue 2, pp. 194-203. DOI: 10.1016/j.jtho.2022.09.222
5、First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations
Author: Paz-Ares, Luis G.; Ciuleanu, Tudor-Eliade; Cobo, Manuel; Bennouna, Jaafar; Schenker, Michael; Cheng, Ying; Juan-Vidal, Oscar; Mizutani, Hideaki; Lingua, Alejo; Reyes-Cosmelli, Felipe; Reinmuth, Niels; Menezes, Juliana; Jassem, Jacek; Protsenko, Svetlana; Richardet, Eduardo; Felip, Enriqueta; Feeney, Kynan; Zurawski, Bogdan; Alexandru, Aurelia; Jimenez, Emmanuel de la Mora; Dakhil, Shaker; Lu, Shun; Reck, Martin; John, Thomas; Hu, Nan; Zhang, Xiaoqing; Sylvester, Judi; Eccles, Laura J.; Grootendorst, Diederik J.; Balli, David; Neely, Jaclyn; Carbone, David P.

Journal: JOURNAL OF THORACIC ONCOLOGY. 2023; Vol. 18, Issue 2, pp. 204-222. DOI: 10.1016/j.jtho.2022.10.014
6、PTEN Loss Expands the Histopathologic Diversity and Lineage Plasticity of Lung Cancers Initiated by Rb1/Trp53 Deletion
Author: Zhang, Letian; Zhu, Xiang; Liu, Congrong; Zhang, Bo; Zheng, Jie; Singh, Prashant K.; Bshara, Wiam; Wang, Jianmin; Gomez, Eduardo Cortes; Zhang, Xiaojing; Wang, Yanqing; Goodrich, David W.

Journal: JOURNAL OF THORACIC ONCOLOGY. 2023; Vol. 18, Issue 3, pp. 324-338. DOI: 10.1016/j.jtho.2022.11.019
7、Respiratory and Cardiometabolic Comorbidities and Stages I to III NSCLC Survival: A Pooled Analysis From the International Lung Cancer Consortium
Author: Garcia-Pardo, Miguel; Chang, Amy; Schmid, Sabine; Dong, Mei; Brown, M. Catherinen; Christiani, David; Tindel, Hilary Aurora; Brennan, Paul; Chen, Chu; Zhang, Jie; Ryan, Brid M.; Zaridze, David; Schabath, Matthew B.; Leal, Leticia Ferro; Reis, Rui Manuel; Tardon, Adonina; Fernandez-Tardon, Guillermo; Shete, Sanjay S.; Andrew, Angeline; Brenner, Hermann; Xu, Wei; Hung, Rayjean J.; Liu, Geoffrey

Journal: JOURNAL OF THORACIC ONCOLOGY. 2023; Vol. 18, Issue 3, pp. 313-323. DOI: 10.1016/j.jtho.2022.10.020
8、Defining Morphologic Features of Invasion in Pulmonary Nonmucinous Adenocarcinoma With Lepidic Growth: A Proposal by the International Association for the Study of Lung Cancer Pathology Committee
Author: Thunnissen, Erik; Beasley, Mary Beth; Borczuk, Alain; Dacic, Sanja; Kerr, Keith M.; Lissenberg-Witte, Birgit; Minami, Yuko; Nicholson, Andrew G.; Noguchi, Masayuki; Sholl, Lynette; Tsao, Ming-Sound; Le Quesne, John; Roden, Anja C.; Chung, Jin-Haeng; Yoshida, Akihiko; Moreira, Andre L.; Lantuejoul, Sylvie; Pelosi, Giuseppe; Poleri, Claudia; Hwang, David; Jain, Deepali; Travis, William D.; Brambilla, Elisabeth; Chen, Gang; Botling, Johan; Bubendorf, Lukas; Mino-Kenudson, Mari; Motoi, Noriko; Chou, Teh Ying; Papotti, Mauro; Yatabe, Yasushi; Cooper, Wendy; Invasion Working Group

Journal: JOURNAL OF THORACIC ONCOLOGY. 2023; Vol. 18, Issue 4, pp. 447-462. DOI: 10.1016/j.jtho.2022.11.026